* suspected or confirmed pregnancy or breastfeeding * severe liver disease * prior use of study drug or other covid treatment within 30 days * hypersensitivity or other contraindication to any components of the study drug * current or expected use of any medication dependent on or inducer of cyp3a4 * current or expected use of supplements or herbs (unless medically necessary) that cannot be temporarily held (period as determined necessary by investigators) * hiv infection with viral load \>50 copies/ml * suspected or confirmed active covid infection within 30 days * history of covid vaccine within 28 days prior to enrollment, or other vaccine (influenza, shingles, etc.) within 14 days of enrollment, or planned use of any vaccine until the primary endpoint has been met (10 weeks) * other medical condition(s) or concomitant therapy that would compromise participant's safety or compliance with the study protocol or significantly confound interpretation of study results, as determined by study investigators * current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device * inability to provide informed consent * currently hospitalized

* suspected or confirmed pregnancy or breastfeeding * severe liver disease * prior use of study drug or other covid treatment within 30 days * hypersensitivity or other contraindication to any components of the study drug * current or expected use of any medication dependent on or inducer of cyp3a4 * current or expected use of supplements or herbs (unless medically necessary) that cannot be temporarily held (period as determined necessary by investigators) * hiv infection with viral load \>50 copies/ml * suspected or confirmed active covid infection within 30 days * history of covid vaccine within 28 days prior to enrollment, or other vaccine (influenza, shingles, etc.) within 14 days of enrollment, or planned use of any vaccine until the primary endpoint has been met (10 weeks) * other medical condition(s) or concomitant therapy that would compromise participant's safety or compliance with the study protocol or significantly confound interpretation of study results, as determined by study investigators * current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device * inability to provide informed consent * currently hospitalized

suspected or confirmed pregnancy or breastfeeding severe liver disease prior use of study drug or other covid treatment within 30 days hypersensitivity or other contraindication to any components of the study drug current or expected use of any medication dependent on or inducer of cyp3a4 current or expected use of supplements or herbs (unless medically necessary) that cannot be temporarily held (period as determined necessary by investigators) hiv infection with viral load >50 copies/ml suspected or confirmed active covid infection within 30 days history of covid vaccine within 28 days prior to enrollment, or other vaccine (influenza, shingles, etc.) within 14 days of enrollment, or planned use of any vaccine until the primary endpoint has been met (10 weeks) other medical condition(s) or concomitant therapy that would compromise participant's safety or compliance with the study protocol or significantly confound interpretation of study results, as determined by study investigators current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device inability to provide informed consent currently hospitalized

suspected or confirmed pregnancy or breastfeeding severe liver disease prior use of study drug or other covid treatment within 30 days hypersensitivity or other contraindication to any components of the study drug current or expected use of any medication dependent on or inducer of cyp3a4 current or expected use of supplements or herbs (unless medically necessary) that cannot be temporarily held (period as determined necessary by investigators) hiv infection with viral load >50 copies/ml suspected or confirmed active covid infection within 30 days history of covid vaccine within 28 days prior to enrollment, or other vaccine (influenza, shingles, etc.) within 14 days of enrollment, or planned use of any vaccine until the primary endpoint has been met (10 weeks) other medical condition(s) or concomitant therapy that would compromise participant's safety or compliance with the study protocol or significantly confound interpretation of study results, as determined by study investigators current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device inability to provide informed consent currently hospitalized

suspected or confirmed pregnancy or breastfeeding severe liver disease prior use of study drug or other covid treatment within 30 days hypersensitivity or other contraindication to any components of the study drug current or expected use of any medication dependent on or inducer of cyp3a4 current or expected use of supplements or herbs (unless medically necessary) that cannot be temporarily held hiv infection with viral load >50 copies/ml suspected or confirmed active covid infection within 30 days history of vaccine (including covid vaccine) within 30 days or planned use of any vaccine until 10 weeks into the study other medical condition(s) or concomitant therapy that would compromise participant's safety or compliance with the study protocol or significantly confound interpretation of study results, as determined by study investigators current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device inability to provide informed consent currently hospitalized

suspected or confirmed pregnancy or breastfeeding severe liver disease prior use of study drug or other covid treatment within 30 days hypersensitivity or other contraindication to any components of the study drug current or expected use of any medication dependent on or inducer of cyp3a4 current or expected use of supplements or herbs (unless medically necessary) that cannot be temporarily held hiv infection with viral load >50 copies/ml suspected or confirmed active covid infection within 30 days history of vaccine (including covid vaccine) within 30 days or planned use of any vaccine until 10 weeks into the study other medical condition(s) or concomitant therapy that would compromise participant's safety or compliance with the study protocol or significantly confound interpretation of study results, as determined by study investigators current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device inability to provide informed consent currently hospitalized

suspected or confirmed pregnancy or breastfeeding severe liver disease suspected or confirmed active covid infection history of vaccine (including covid) within 30 days

suspected or confirmed pregnancy or breastfeeding severe liver disease suspected or confirmed active covid infection history of vaccine (including covid) within 30 days